TY - JOUR
T1 - Engineered resveratrol nanoantioxidants
T2 - intestinal targeted oral delivery system of mesalazine for inflammatory bowel disease via spatiotemporal-ecological regulation
AU - Yan, Jun
AU - Yu, Tianyu
AU - Zhao, Xiaoping
AU - Liu, Zhicheng
AU - Sun, Heng
AU - Zhang, Xiaojiang
AU - Liu, Yichen
AU - Wang, Wen
AU - Meng, Lingjie
AU - She, Junjun
AU - Jing, Xunan
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Inflammatory bowel disease (IBD) is a life-threatening condition associated with excessive reactive oxygen species (ROS), chronic mucosal inflammation, and gut microbiota dysbiosis. The therapeutic potential of resveratrol (Rv) and mesalazine (Mz) is limited by poor solubility, nonspecific distribution, and low delivery efficiency. To overcome these challenges, we introduce an integrated nanotherapeutic approach where we modify hyaluronic acid (HA) onto the surface of Mz-encapsulated mesoporous Rv-crosslinked polyphosphazene nanobowl (named PHRv@Mz@HA), for multitarget therapy in IBD. Benefiting from the negatively charged surface of HA coating and abundant phenolic hydroxyl groups in PHRv@Mz@HA, it allows for prolonged retention to the gastrointestinal tract and targeted accumulation of the nanomedication to the positively charged inflamed colon regions through electrostatic interactions and bioadhesion. Subsequently, PHRv@Mz@HA specifically binds to CD44-overexpressed inflammatory cells (especially macrophages), thus significantly alleviating oxidative stress and inflammation at IBD lesions. Specifically, mechanistic studies revealed that PHRv@Mz@HA exerted its effects through activating Nrf2/HO-1 signaling pathway for ROS scavenging, while suppressing the inflammatory response by down-regulating TLR4/NF-κB signaling pathway. In the mice models of dextran sulfate sodium- and trinitrobenzenesulfonic acid-induced acute colitis demonstrated that oral administration of PHRv@Mz@HA achieved outperformed therapeutic effects compared with standard drug Mz, as evidenced by elimination of oxidative stress, decreased colonic and systemic inflammation, repaired intestinal barrier, and restored gut microbiota balance. By integrating targeted delivery with bioresponsive release of natural medicine, this work offered a safe and effective intervention for IBD treatment.
AB - Inflammatory bowel disease (IBD) is a life-threatening condition associated with excessive reactive oxygen species (ROS), chronic mucosal inflammation, and gut microbiota dysbiosis. The therapeutic potential of resveratrol (Rv) and mesalazine (Mz) is limited by poor solubility, nonspecific distribution, and low delivery efficiency. To overcome these challenges, we introduce an integrated nanotherapeutic approach where we modify hyaluronic acid (HA) onto the surface of Mz-encapsulated mesoporous Rv-crosslinked polyphosphazene nanobowl (named PHRv@Mz@HA), for multitarget therapy in IBD. Benefiting from the negatively charged surface of HA coating and abundant phenolic hydroxyl groups in PHRv@Mz@HA, it allows for prolonged retention to the gastrointestinal tract and targeted accumulation of the nanomedication to the positively charged inflamed colon regions through electrostatic interactions and bioadhesion. Subsequently, PHRv@Mz@HA specifically binds to CD44-overexpressed inflammatory cells (especially macrophages), thus significantly alleviating oxidative stress and inflammation at IBD lesions. Specifically, mechanistic studies revealed that PHRv@Mz@HA exerted its effects through activating Nrf2/HO-1 signaling pathway for ROS scavenging, while suppressing the inflammatory response by down-regulating TLR4/NF-κB signaling pathway. In the mice models of dextran sulfate sodium- and trinitrobenzenesulfonic acid-induced acute colitis demonstrated that oral administration of PHRv@Mz@HA achieved outperformed therapeutic effects compared with standard drug Mz, as evidenced by elimination of oxidative stress, decreased colonic and systemic inflammation, repaired intestinal barrier, and restored gut microbiota balance. By integrating targeted delivery with bioresponsive release of natural medicine, this work offered a safe and effective intervention for IBD treatment.
KW - Anti-inflammatory
KW - Gut microbiota regulation
KW - Inflammatory bowel disease
KW - ROS scavenging
KW - Resveratrol-polyphosphazene
UR - https://www.scopus.com/pages/publications/105023584096
U2 - 10.1007/s42114-025-01519-3
DO - 10.1007/s42114-025-01519-3
M3 - 文章
AN - SCOPUS:105023584096
SN - 2522-0128
VL - 8
JO - Advanced Composites and Hybrid Materials
JF - Advanced Composites and Hybrid Materials
IS - 6
M1 - 458
ER -